Shire gains on Firazyr approval
Washington – British Shire plc gained more than 10% in late August on the London Stock Exchange after the US FDA approved Firazyr (icatibant) for acute attacks of hereditary angioedema. The compound was developed by Berlin-based Jerini AG, which was bought by Shire. Earlier in August, Shire had discontinued development of its Dermagraft cell therapy to treat venous leg ulcers after the engineered skin substitute missed a primary endpoint of complete healing in a Phase III trial. Shire had gained the product – which is marketed in the US for treating diabetic foot ulcers – through its US$750m acquisition of Advanced BioHealing Inc in June.